MPNs

The FDA prioritizes Orca-T's review for treating hematologic malignancies, promising improved survival and reduced complications compared with traditional therapies.

Luke Fletcher, MD, reviews updates in anemia-predominant MDS and the 2025 polling results from MDS Case-Based Roundtable events.

MNV-201 gains FDA fast track designation for myelodysplastic syndromes, promising expedited development and potential breakthroughs in treatment.

A study reveals that azacitidine, especially in combination with ruxolitinib, improves survival in patients with advanced myeloproliferative neoplasms.

FDA fast-tracks CER-1236, a novel immunotherapy for acute myeloid leukemia, enhancing its development and potential market entry.

New research unveils a promising monoclonal antibody therapy targeting CALR mutations in essential thrombocythemia, aiming to improve patient outcomes.

The IOS-202/azacitidine combination revealed a complete response of 27.8% and an overall response rate of 66.7% in patients with chronic myelomonocytic leukemia.

Study reveals alarming treatment gaps in high-risk Myelodysplastic Syndromes, highlighting disparities and adherence issues that impact patient outcomes.

A recent study uncovers disparities in treatment patterns for myelodysplastic syndromes, revealing critical insights into patient outcomes and care access.

VGT-1849B receives FDA orphan drug designation, promising a targeted treatment for polycythemia vera with improved safety and efficacy.

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating acute myeloid leukemia.

FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising treatment options.

A groundbreaking phase 3 study for lisaftoclax offers hope for first-line treatment of higher-risk myelodysplastic syndrome, addressing a critical medical need.

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high efficacy and safety.

A new drug for low-risk MDS is showing a surprising benefit: it's not just improving quality of life, but also extending patients' lives.

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Guillermo Garcia-Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic syndrome.

Menin inhibitors emerge as a breakthrough in treating acute myeloid leukemia, showcasing promising results at the 2025 EHA Congress.

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high transfusion dependency.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk myelodysplastic syndrome treated with bexmarilimab.

New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, improving patient outcomes significantly.

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed or refractory patients with AML or MDS.

Luspatercept shows promise in improving anemia in myelofibrosis patients, despite not meeting primary trial endpoints, highlighting ongoing treatment challenges.

FDA grants orphan drug designation to ICT01, a promising immunotherapy for acute myeloid leukemia, targeting unmet needs in older patients.

FDA's new draft guidance enhances drug development for myelodysplastic syndromes, focusing on trial design, patient selection, and safety reporting.